

Javier Garca-Samaniego

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7168646/javier-garcia-samaniego-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136
papers

6,608
citations

38
h-index

79
g-index

153
ext. papers

7,993
ext. citations

4.4
avg, IF

4.72
L-index

#	Paper	IF	Citations
136	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review.. <i>Scientific Reports</i> , 2021 , 11, 24133	4.9	2
135	Hepatitis C reflex testing in Spain in 2019: A story of success. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021 , 39, 119-126	0.1	
134	Hepatitis C reflex testing in Spain in 2019: A story of success. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021 , 39, 119-126	0.9	7
133	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021 , 41, 2076-2086	7.9	5
132	One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 462-469	6.1	4
131	Mild AST elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort. <i>Revista Española De Enfermedades Digestivas</i> , 2021 , 113, 780-786	0.9	1
130	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. <i>Journal of Infectious Diseases</i> , 2020 , 222, 726-733	7	26
129	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020 , 73, 17-25	13.4	26
128	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020 , 43, 559-587	0.1	0
127	Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 158-166	6.1	12
126	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. <i>Journal of Hepatology</i> , 2020 , 72, 816-827	13.4	88
125	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020 , 174, 104694	10.8	20
124	SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. <i>Journal of Hepatology</i> , 2020 , 73, 1262-1263	13.4	12
123	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 559-587	0.9	6
122	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46
121	Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. <i>PLoS ONE</i> , 2019 , 14, e0221567	3.7	2
120	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019 , 71, 666-672	13.4	35

119	HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz214	1	3
118	Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019 , 37, 222-230	0.1	
117	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 579-592	0.1	2
116	Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment. <i>World Journal of Gastroenterology</i> , 2019 , 25, 5883-5896	5.6	3
115	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 579-592	0.9	13
114	Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 222-230	0.9	8
113	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 55-64	3.4	16
112	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 383-403	18.8	702
111	Expression of PD-1 and Tim-3 markers of T-cell exhaustion is associated with CD4 dynamics during the course of untreated and treated HIV infection. <i>PLoS ONE</i> , 2018 , 13, e0193829	3.7	20
110	Hepatitis E virus in neurological disorders: a case of Parsonage-Turner syndrome. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018 , 110, 402-403	0.9	3
109	According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1 HCV-Specific CD8 Cell Reactivity. <i>Journal of Virology</i> , 2018 , 92,	6.6	12
108	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1260-1270	6.1	43
107	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 161-176	18.8	1196
106	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 784-793	4	48
105	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 945-949.e1	6.9	18
104	Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. <i>Medicina Clínica</i> , 2017 , 148, 277-282	1	23
103	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. <i>Hepatology</i> , 2017 , 65, 1810-1822	11.2	64
102	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017 , 66, 1138-1148	13.4	131

101	Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. <i>Aids</i> , 2017 , 31, 1253-1260	3.5	25
100	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017 , 37, 1823-1832	7.9	8
99	Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2017 , 37, 278-286	3.5	1
98	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 325-336	18.8	153
97	HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. <i>PLoS ONE</i> , 2017 , 12, e0173943	3.7	10
96	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 779-89	3	20
95	Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype. <i>World Journal of Gastroenterology</i> , 2016 , 22, 3165-74	5.6	7
94	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. <i>PLoS ONE</i> , 2016 , 11, e0168544	3.7	1
93	Hepatitis C virus-mediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity. <i>Journal of Hepatology</i> , 2015 , 63, 312-9	13.4	12
92	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 46-54	2.2	4
91	High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 219-26	9.7	64
90	Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study. <i>PLoS ONE</i> , 2015 , 10, e0122613	3.7	1
89	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015 , 14, 477-486	3.1	1
88	Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 65-73	4.6	31
87	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014 , 13, 356-363	3.1	15
86	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. <i>Gastroenterología Y Hepatología</i> , 2013 , 36, 555-64	0.9	1
85	Factors associated with early virological response to peginterferon-2a/ribavirin in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2013 , 19, 1943-52	5.6	7
84	Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 1705-10	4	

83	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 535-42	2.2	21
82	Acute hepatitis C in Spain: a retrospective study of 131 cases. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012 , 104, 21-8	0.9	7
81	Pathogenesis of occult chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2011 , 17, 1543-8	5.6	21
80	Response to: Is the Study Power Enough to Say 'No Difference'? by Geib et al. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, e37-e38	3.1	
79	Elevated TGF- β levels might protect HCV/ HIV-coinfected patients from liver fibrosis. <i>European Journal of Clinical Investigation</i> , 2011 , 41, 70-6	4.6	20
78	Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 641-4	5.1	9
77	HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 57, 1-8	3.1	20
76	Clinical significance of occult hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2011 , 17, 1549-52	5.6	17
75	Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2164-72; quiz 2173	0.7	53
74	Liver complications have reached a plateau as cause of hospital admission and death in HIV patients in Madrid. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 383-5	1.6	8
73	Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1397-401	11.6	29
72	Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. <i>Hepatology</i> , 2009 , 50, 1702-8	11.2	110
71	Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. <i>Clinical and Experimental Immunology</i> , 2009 , 155, 35-43	6.2	38
70	Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 790-5	3.4	31
69	Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 895-6	3.4	41
68	Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 339-45	6.9	32
67	Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. <i>Antiviral Therapy</i> , 2009 , 14, 23-32	1.6	50
66	Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 363-9	3.4	21

65	Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 710-5	3.4	13
64	Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 626-7	5.1	15
63	Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. <i>Aids</i> , 2008 , 22, 15-21	3.5	47
62	Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 165-72	3.4	71
61	Management of hepatitis B virus co-infection on and off antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , 2008 , 5, 86-93	5.9	7
60	Emerging drugs for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2008 , 13, 1-19	3.7	39
59	Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?. <i>Antiviral Therapy</i> , 2008 , 13, 97-102	1.6	22
58	Does Treatment of Hepatitis B virus (HBV) Infection Reduce Hepatitis Delta virus (HDV) Replication in HIV-HBV-HDV-Coinfected Patients?. <i>Antiviral Therapy</i> , 2008 , 13, 97-102	1.6	59
57	Antiretroviral-Associated Portal Hypertension: A New Clinical Condition? Prevalence, Predictors and Outcome. <i>Antiviral Therapy</i> , 2008 , 13, 103-108	1.6	56
56	The implications of antiviral drugs with activity against hepatitis B virus and HIV. <i>Current Opinion in Internal Medicine</i> , 2007 , 20, 621-8		3
55	Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus. <i>Journal of Medical Virology</i> , 2007 , 79, 503-10	19.7	23
54	Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Infection</i> , 2007 , 54, 173-9	18.9	30
53	Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 387-91	3.4	29
52	Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 44, 557-61	3.1	46
51	Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 972-82	1.6	156
50	Management and therapy of chronic hepatitis C in HIV. <i>Current Opinion in HIV and AIDS</i> , 2007 , 2, 482-8	4.2	
49	Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46, 279-82	3.1	49
48	Outbreak of syphilis, but not of acute hepatitis C, among HIV-infected homosexual men in Madrid. <i>HIV Clinical Trials</i> , 2007 , 8, 98-101		17

47	Evolution of T-cell Responses to Hepatitis C Virus (HCV) during Pegylated Interferon plus Ribavirin treatment in HCV-Monoinfected and in HCV/HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 459-468	1.6	7
46	Premature Treatment Discontinuation in HIV/HCV-Coinfected Patients Receiving Pegylated Interferon plus Weight-Based Ribavirin. <i>Antiviral Therapy</i> , 2007 , 12, 469-476	1.6	11
45	Severe liver disease associated with prolonged exposure to antiretroviral drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 42, 177-82	3.1	126
44	Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 825-9	1.6	22
43	Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. <i>Gastroenterology</i> , 2006 , 131, 451-60	13.3	311
42	Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less. <i>Infectious Disorders - Drug Targets</i> , 2006 , 6, 57-88	1.1	
41	Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 851-7	3.4	10
40	Complications in treating chronic hepatitis B in patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2831-42	4	1
39	Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 39, 401-5	3.1	67
38	New paradigms in the management of HIV and hepatitis C virus coinfection. <i>Current Opinion in Infectious Diseases</i> , 2005 , 18, 550-60	5.4	11
37	Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1245-8	7	7
36	Impact of Ribavirin Exposure on Early Virological Response to Hepatitis C Therapy in HIV-Infected Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005 , 10, 657-662	1.6	18
35	Response to Interferon-Based Therapies in HIV-Infected Patients with Chronic Hepatitis C Due to Genotype 4. <i>Antiviral Therapy</i> , 2005 , 10, 167-170	1.6	8
34	Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. <i>Clinical Infectious Diseases</i> , 2004 , 38, 128-33	11.6	249
33	Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 351-3	1.6	36
32	Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 2-17	3.4	46
31	Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. <i>Drug Safety</i> , 2004 , 27, 7-24	5.1	10
30	High prevalence of seropositivity to a major allergen of <i>Anisakis simplex</i> , Ani s 1, in dyspeptic patients. <i>Vaccine Journal</i> , 2004 , 11, 115-8		17

29	Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin. <i>Antiviral Therapy</i> , 2004 , 9, 505-509	1.6	21
28	Long-Term Follow-Up of HIV-Infected Patients with Chronic Hepatitis C Virus Infection Treated with Interferon-Based Therapies. <i>Antiviral Therapy</i> , 2004 , 9, 987-992	1.6	38
27	Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2003 , 17, 1023-8	3.5	143
26	Treatment of chronic hepatitis C virus infection. <i>Aids</i> , 2003 , 17, 751-753	3.5	25
25	Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 32, 465-6	3.1	1
24	Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 1083-9	1.6	20
23	Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 657-9	1.6	31
22	Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000. <i>HIV Clinical Trials</i> , 2002 , 3, 99-114		16
21	Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. <i>Aids</i> , 2002 , 16, 493-5	3.5	11
20	Management of hepatitis C in HIV-infected persons. <i>Antiviral Research</i> , 2001 , 52, 189-98	10.8	23
19	Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 1467-71	1.6	171
18	Re: García-Samaniego et al.--Hepatocellular carcinoma in patients with HCV-HIV coinfection. <i>American Journal of Gastroenterology</i> , 2001 , 96, 3441-2	0.7	1
17	Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001 , 96, 179-83	0.7	169
16	Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , 2001 , 33, 1793-5	11.6	34
15	Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. <i>Journal of Viral Hepatitis</i> , 2000 , 7, 403-8	3.4	29
14	Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. <i>Aids</i> , 2000 , 14, 212	3.5	49
13	Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2000 , 14, 2409-10	3.5	6
12	Interferon Plus Ribavirin in HIV-Infected Patients With Chronic Hepatitis C. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 22, 308	3.1	8

11	Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. <i>European Journal of Epidemiology</i> , 1999 , 15, 1-4	12.1	126
10	Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. <i>Journal of Hepatology</i> , 1999 , 31 Suppl 1, 119-23	13.4	49
9	Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 22, 308-9	3.1	14
8	Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients. <i>Journal of Hepatology</i> , 1998 , 28, 526-7	13.4	42
7	Hepatotoxicity after introduction of highly active antiretroviral therapy. <i>Aids</i> , 1998 , 12, 1256	3.5	144
6	Co-infection with several HCV genotypes enhances liver damage in patients with chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. <i>Journal of Infection</i> , 1997 , 35, 202-3	18.9	1
5	A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group. <i>Journal of Infection</i> , 1997 , 35, 225-30	18.9	15
4	Hepatitis C viraemia in HIV-infected patients. Hepatitis-HIV Spanish Study Group. <i>Aids</i> , 1996 , 10, 922-3	3.5	7
3	Circulating hepatitis C virus genotypes in Spain. The Hepatitis/HIV Spanish Study Group. <i>Vox Sanguinis</i> , 1996 , 70, 180-1	3.1	8
2	Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. <i>Clinical Infectious Diseases</i> , 1996 , 23, 585-91	11.6	159
1	Human Immunodeficiency Virus and the Liver974-987		0